ACTICOR BIOTECH (FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today provides an update on the current receivership proceedings.
To enable the Company to continue its search for new investors or partners to support its new development plan in STEMI (ST-Elevation Myocardial Infarction), the court-appointed administrator had granted mid-October 2024 an extension until Tuesday November 5, 2024, to the call for bids published on September 13, for a continuation or disposal plan.
To date, the court-appointed administrator has received no proposal from a buyer. The Company is therefore pursuing its search for a solution to support the development of glenzocimab in STEMI, and the 6-month observation period opened on August 6, 2024, is ongoing.
As a reminder, on 6 August 2024, the Paris Commercial Court had ordered the opening of receivership proceedings. The purpose of these proceedings is to enable the Company to assess all the options available to it to pursue its development, the development of its product, glenzocimab, and its search for financing and partners. As already mentioned, this procedure will also enable the Company to finance its operations until January 2025.
The Company will continue to keep the market informed of developments in the current receivership proceedings and calls on investors to follow closely future communications concerning its progress.
